ReviewRadiology2023
Open access · greenAbstract readReview
In one paragraph
Review in Radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Diagnostic Performance of Positron Emission Tomography in the Assessment of Systemic Amyloidosis: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Archivos de cardiologia de Mexico · 2024Guideline
- Four Key Challenges After a Decade of Consecutive Paradigm Shifts in Wild-Type Transthyretin Amyloid Cardiomyopathy: From Rarely Found to Never Missed.Circulation reports · 2026Review
- Expert Consensus and Clinical Pathway Recommendations for Transthyretin Amyloid Cardiomyopathy in Malaysia.International journal of heart failure · 2026Review
- Melatonergic Modulation of SIRT1-Nrf2 Signaling Protects Against Doxorubicin-Induced Hepatic Injury in Rats.Biomedicines · 2026Article
- Impact of cardiac amyloidosis on survival in aortic stenosis patients undergoing TAVR: a systematic review and reconstructed time-to-event meta-analysis.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- Brain Amyloid Deposition Is Negatively Associated with Cardiac Amyloid Retention in Apo E4 Carriers: A Pilot Study.Molecular imaging and biology · 2026Article
- Clinical impact and prognostic implications of concurrent amyloid deposition in patients with POEMS syndrome: A single-center retrospective study.Annals of hematology · 2026Article
- Biomarker-Imaging Dissociation in Wild-Type Cardiac Amyloidosis after Treatment with Patisiran.Arquivos brasileiros de cardiologia · 2026Article
- Expert consensus: first multidisciplinary consensus on nuclear cardiology.Archivos de cardiologia de Mexico · 2026Article
- Misdiagnosis of 99mTc-PYP-positive Danon disease as ATTR-CA: a case report and molecular imaging pitfalls.BMC cardiovascular disorders · 2025Article
- Concurrent light chain and transthyretin cardiac amyloidosis: A case report and review of the literature.Medicine · 2025Review
- Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM.ESC heart failure · 2025Article
- Advances in imaging-based diagnosis, prognosis, and response assessment in cardiac amyloidosis: a comprehensive multimodality review.Annals of nuclear medicine · 2025Review
- Article
- Cardiopulmonary Exercise Testing Correlates with Quantitative Left Ventricular [Journal of clinical medicine · 2025Article
- Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis.Reviews in cardiovascular medicine · 2025Article
- Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters.Diagnostics (Basel, Switzerland) · 2025Article
- Recent Advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis.Current cardiology reports · 2024Review
- Novel Insights into Non-Invasive Diagnostic Techniques for Cardiac Amyloidosis: A Critical Review.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Yiu Ming KhorFrom the Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore (Y.M.K.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (Y.M.K., V.S., M.F.D.C., S.D.), Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine (S.A.M.C., R.H.F., S.D.), and CV Imaging Program, Cardiovascular Division and Department of Radiology (S.A.M.C., V.S., M.F.D.C., S.D.), Brigham and Women's Hospital and Harvard Medical School, 70 Francis St, Boston, MA 02115; and Midwest Heart and Vascular Specialists, HCA Midwest Health, Kansas City, Mo (V.S.).ORCID 0000-0002-4307-1349
Sarah A M CuddyFrom the Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore (Y.M.K.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (Y.M.K., V.S., M.F.D.C., S.D.), Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine (S.A.M.C., R.H.F., S.D.), and CV Imaging Program, Cardiovascular Division and Department of Radiology (S.A.M.C., V.S., M.F.D.C., S.D.), Brigham and Women's Hospital and Harvard Medical School, 70 Francis St, Boston, MA 02115; and Midwest Heart and Vascular Specialists, HCA Midwest Health, Kansas City, Mo (V.S.).ORCID 0000-0002-2124-2151
Vasvi SinghFrom the Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore (Y.M.K.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (Y.M.K., V.S., M.F.D.C., S.D.), Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine (S.A.M.C., R.H.F., S.D.), and CV Imaging Program, Cardiovascular Division and Department of Radiology (S.A.M.C., V.S., M.F.D.C., S.D.), Brigham and Women's Hospital and Harvard Medical School, 70 Francis St, Boston, MA 02115; and Midwest Heart and Vascular Specialists, HCA Midwest Health, Kansas City, Mo (V.S.).
Rodney H FalkFrom the Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore (Y.M.K.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (Y.M.K., V.S., M.F.D.C., S.D.), Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine (S.A.M.C., R.H.F., S.D.), and CV Imaging Program, Cardiovascular Division and Department of Radiology (S.A.M.C., V.S., M.F.D.C., S.D.), Brigham and Women's Hospital and Harvard Medical School, 70 Francis St, Boston, MA 02115; and Midwest Heart and Vascular Specialists, HCA Midwest Health, Kansas City, Mo (V.S.).
Marcelo F Di CarliFrom the Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore (Y.M.K.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (Y.M.K., V.S., M.F.D.C., S.D.), Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine (S.A.M.C., R.H.F., S.D.), and CV Imaging Program, Cardiovascular Division and Department of Radiology (S.A.M.C., V.S., M.F.D.C., S.D.), Brigham and Women's Hospital and Harvard Medical School, 70 Francis St, Boston, MA 02115; and Midwest Heart and Vascular Specialists, HCA Midwest Health, Kansas City, Mo (V.S.).ORCID 0000-0003-3119-025X
Sharmila DorbalaFrom the Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore (Y.M.K.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology (Y.M.K., V.S., M.F.D.C., S.D.), Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine (S.A.M.C., R.H.F., S.D.), and CV Imaging Program, Cardiovascular Division and Department of Radiology (S.A.M.C., V.S., M.F.D.C., S.D.), Brigham and Women's Hospital and Harvard Medical School, 70 Francis St, Boston, MA 02115; and Midwest Heart and Vascular Specialists, HCA Midwest Health, Kansas City, Mo (V.S.).ORCID 0000-0003-1462-1185
Brigham and Women's Hospital · US
Funding
Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late LifeR01HL150342 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, SHAH, AMIL M · 2020 to 2023
$4.1MMolecular Imaging of Primary Amyloid CardiomyopathyR01HL130563 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA, FALK, RODNEY H · 2016 to 2019
$3.3MMentoring Patient Oriented Research in Innovative Imaging and High-dimensional Data Approaches to Improve Outcomes in Cardiac AmyloidosisK24HL157648 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DORBALA, SHARMILA · 2021 to 2025
$612kNHLBI NIH HHS K24 HL157648NHLBI NIH HHS R01 HL130563NHLBI NIH HHS R01 HL150342
Abstract
Transthyretin cardiac amyloidosis (ATTR-CA) is an overlooked cause of heart failure, with substantial morbidity and mortality. The emergence of several novel therapies has fueled the interest in early and accurate diagnosis of ATTR-CA so that potentially life-saving pharmacologic therapy can be administered in a timely manner. The most promising imaging modality and biomarker is SPECT imaging with technetium 99m (
Indexed as
Amyloid Neuropathies, FamilialAmyloidosisCardiomyopathiesDiphosphatesDiphosphonatesHeartHumansPrealbuminRadionuclide ImagingRadiopharmaceuticalsDiphosphatesDiphosphonatesdiphosphoric acidhydroxymethanediphosphonic acidPrealbuminRadiopharmaceuticals
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.